Prostate specific antigen (PSA) is a sensitive and specific serum marker for prostate tissue. Serial measurements are routinely obtained to detect early disease recurrence in men who have received definitive treatment for localized disease. (See "Follow-up surveillance during and after treatment for prostate cancer".)
Monitoring PSA after definitive treatment of localized prostate cancer leads to the identification of men with a PSA-only (biochemical) recurrence. In this situation, increases in serum PSA are not accompanied by signs or symptoms of recurrent or disseminated disease. For men in whom there is a significant likelihood that disease is confined to the prostatic bed, salvage therapy may result in prolonged disease-free survival.
The use of salvage RT for men who have a rising PSA following radical prostatectomy for early stage disease will be reviewed here. Other topics relevant to patients with a rising PSA include:
●(See "Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification".)
●(See "Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation".)